We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $8.33, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily gain of 1.75%. Meanwhile, the Dow experienced a rise of 1.86%, and the technology-dominated Nasdaq saw an increase of 2.54%.
The infectious disease drug developer's shares have seen a decrease of 0.24% over the last month, not keeping up with the Medical sector's gain of 3.73% and outstripping the S&P 500's loss of 1.63%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.84 per share and a revenue of $540.09 million, representing changes of +40% and +5.86%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics is currently a Zacks Rank #5 (Strong Sell).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 10.1. This expresses a discount compared to the average Forward P/E of 20.9 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $8.33, marking a -1.83% move from the previous day. This change lagged the S&P 500's daily gain of 1.75%. Meanwhile, the Dow experienced a rise of 1.86%, and the technology-dominated Nasdaq saw an increase of 2.54%.
The infectious disease drug developer's shares have seen a decrease of 0.24% over the last month, not keeping up with the Medical sector's gain of 3.73% and outstripping the S&P 500's loss of 1.63%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.84 per share and a revenue of $540.09 million, representing changes of +40% and +5.86%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics is currently a Zacks Rank #5 (Strong Sell).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 10.1. This expresses a discount compared to the average Forward P/E of 20.9 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.